{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:50:44Z","timestamp":1791319844630,"version":"4.3.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jneuroim.2026.579029","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:35:08Z","timestamp":1783985708000},"page":"579029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world risks of neurotoxicity with immune checkpoint inhibitors compared with standard chemotherapy"],"prefix":"10.1016","volume":"419","author":[{"given":"Alexandra","family":"Balshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang-James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna S.","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.jneuroim.2026.579029_bb0005","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/noajnl\/vdab107","article-title":"A review of neurotoxicities associated with immunotherapy and a framework for evaluation","volume":"3","author":"Burton","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"issue":"25","key":"10.1016\/j.jneuroim.2026.579029_bb0010","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579029_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.jneuroim.2026.579029_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer (Oxford, England\u202f: 1990)"},{"issue":"5","key":"10.1016\/j.jneuroim.2026.579029_bb0025","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.jneuroim.2026.579029_bb0030","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.jneuroim.2026.579029_bb0035","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41568-025-00863-2","article-title":"Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity","volume":"25","author":"Karschnia","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.jneuroim.2026.579029_bb0040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"issue":"10183","key":"10.1016\/j.jneuroim.2026.579029_bb0045","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jneuroim.2026.579029_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103011","article-title":"Immune checkpoint inhibitor-related neurotoxicity: incidence and management. A systematic review and meta-analysis","volume":"140","author":"Nielsen","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.jneuroim.2026.579029_bb0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41582-024-01001-6","article-title":"Peripheral nervous system immune-related adverse events due to checkpoint inhibition","volume":"20","author":"O\u2019Hare","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.jneuroim.2026.579029_bb0060","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open."},{"issue":"9","key":"10.1016\/j.jneuroim.2026.579029_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70198","article-title":"TriNetX Dataworks-USA: overview of a multi-purpose, de-identified, federated electronic health record real-world data and analytics network and comparison to the US census","volume":"34","author":"Stein","year":"2025","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"10","key":"10.1016\/j.jneuroim.2026.579029_bb0070","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2026.579029_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2025-335998","article-title":"Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist","author":"Willis","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826001785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572826001785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:58:10Z","timestamp":1791316690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572826001785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"alternative-id":["S0165572826001785"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579029","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world risks of neurotoxicity with immune checkpoint inhibitors compared with standard chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2026.579029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"579029"}}